source
- Biotech Index Retraces Gains as Weak Trial Data and Market Fears WeighBioPharma Dive’s latest data‑visualization piece examines why biotech stocks have slipped recently and highlights the rapid pace of startup acquisitions this year. The XBI index, a barometer for b…
- CBER Director Karim Mikhail Aims to Restore Stability After Turbulent Leadership ChangesThe FDA's Center for Biologics Evaluation and Research (CBER) is working to regain stability after a period of rapid leadership turnover. Karim Mikhail, who was confirmed as the permanent director…